• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution
rhSOD

Unichem Labs gets tentative US FDA approval for Sitagliptin Tablets USP

expresspharmaJuly 12, 2021

Tag: Unichem , Januvia , Sitagliptin

Unichem Laboratories has received tentative approval for ANDA of Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg from the United States Food and Drug Administration (USFDA) for a generic version of Januvia (sitagliptin) tablets, 25 mg, 50 mg, and 100 mg, of Merck Sharpe and Dohme Corp (Merck).

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The product will be commercialised from Unichem’s Goa Plant on receipt of full approval.

Previous:Bayer gets US FDA nod for KERENDIA (finerenone) to treat CKD associated with type 2 diabetes

Next:ICMR proposes clinical trial along with Oxford University to evaluate COVID-19 therapy

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Unichem Labs gets tentative US FDA approval for Sitagliptin Tablets USP | Pharmasources.com

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

You may like
More>>

Sitagliptin

Sitagliptin
Sitagliptin

Sitagliptin
Januvia

Januvia
sitagliptin intermediate 4

sitagliptin intermediate 4
Sitagliptin

Sitagliptin
Sitagliptin phosphate monohydrate

Sitagliptin phosphate monohydrate
Sitagliptin Impurity 48

Sitagliptin Impurity 48
Sitagliptin monohydrate

Sitagliptin monohydrate
Sitagliptin phosphate monohydrate

Sitagliptin phosphate monohydrate
Sitagliptin Base/ Phosphate

Sitagliptin Base/ Phosphate

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service